Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Liraglutide And Semaglutide Market, and What Factors Will Drive It?
The market share of liraglutide and semaglutide has seen a swift expansion in the preceding years. It is projected to inflate from $15.19 billion in 2024 to $16.94 billion in 2025, with a compound annual growth rate (CAGR) of 11.5%. Factors contributing to this growth over the historic period include a rising incidence of diabetes, the surge in obesity-related ailments, an increase in clinical trials, enhanced investments in diabetes research and development, and a growing client call for accessible treatment alternatives.
We anticipate a sharp increase in the liraglutide and semaglutide market size in the forthcoming years with a projection to reach$26.07 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 11.4%. Reasons for this growth in the forecast period can be traced back to the growing use of GLP-1 receptor agonists, hike in healthcare spending, the broadening of pharmaceutical firms’ product offerings, escalated disposable incomes, and an increasing number of elderly people susceptible to diabetes. Noteworthy trends predicted during this period encompass the assimilation of digital health platforms, application of personalized dosing approaches, progress in drug delivery technologies, the emergence of biosimilar versions, and incorporation of artificial intelligence into treatment decision-making processes.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp
What External and Internal Drivers Are Contributing to the Growth of theLiraglutide And Semaglutide Market?
The increase in diabetes cases is anticipated to boost the liraglutide and semaglutide market growth. Diabetes, a long-term ailment, manifests as high blood sugar levels due to the body’s insulin resistance and deficiency. The escalating number of diabetics can be attributed to inactive lifestyles, unhealthy nutrition, and genetic factors. Liraglutide and semaglutide play a vital role in providing efficient blood glucose control and minimizing the risk of diabetes-related complications for diabetic individuals. For instance, the National Health Service, a government department in the UK, revealed in June 2024, that in 2023, they had recognized an extra 549,000 individuals in England with a heightened risk of contracting type 2 diabetes. This took the total count of people with non-diabetic hyperglycemia or pre-diabetes registered with a GP to 3,615,330. An impressive surge compared to 3,065,825 in 2022, indicating an almost 20% increase. Consequently, the growing number of diabetes patients spurs the growth of the liraglutide and semaglutide markets.
What Segment Types Define the Liraglutide And Semaglutide Market Structure?
The liraglutide and semaglutidemarket covered in this report is segmented –
1) By Type: Pills; Liquid
2) By Administration: Parenteral; Oral
3) By Application: Type 2 Diabetes Mellitus; Obesity; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Pills: Oral Tablets (Liraglutide, Semaglutide); Extended-Release Oral Formulations
2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide); Pre-Filled Syringes; Vials For Injection
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Liraglutide And Semaglutide Market?
North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Liraglutide And Semaglutide Market?
Leading firms in the liraglutide and semaglutide industry are advancing the development of anti-diabetic biosimilar drugs to improve glucose management and lessen cardiovascular threats for individuals diagnosed with diabetes. These anti-diabetic biosimilars, which are affordable, nearly identical versions of original diabetes biological drugs, are designed to provide the same health advantages as their counterparts. For example, Glenmark Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced a biosimilar to the widely-used anti-diabetic medication, Liraglutide, in January 2024, marking its first launch in India. This biosimilar of Liraglutide aids in better glycemic control in adults suffering from type 2 diabetes mellitus. Its introduction reduces the cost of daily therapy, thus broadening its accessibility to more patients across the country. With a price tag of roughly INR 100 for a standard 1.2 mg dose each day, this treatment decreases therapy expenses by nearly 70%, with a prescription being necessary for its purchase.
View the full report here:
https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report
What Is the Definition of the Liraglutide And Semaglutide Market?
Liraglutide and semaglutide refer to medications categorized as glucagon-like peptide-1 (GLP-1) receptor agonists, prescribed primarily for managing type 2 diabetes mellitus and utilized to improve glycemic control in adults with this condition. They are injectable medications and are typically used when other treatments for diabetes or obesity have not been effective enough. They are often part of a comprehensive treatment plan that includes diet, exercise, and other medications as needed.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18400
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model